


EFFECTIVENESS AND PERSISTENCE OF SECUKINUMAB IN PSORIATIC ARTHRITIS: COMPARISON BETWEEN BIOLOGIC-NAÏVE AND PREVIOUSLY TREATED PATIENTS

M. MUÑOZ VILLASUR, C. RODRÍGUEZ-TENREIRO RODRÍGUEZ, V. GARCIA JIMENEZ, C. FADÓN HERRERA, C. DÍAZ ROMERO, I. MARAY MATEOS, A.M. GÓMEZ MATO, M. LATASA BERASATEGUI, C. ESPARRAGO FERNANDEZ, M. VARELA FERREIRO, A. LOZANO BLÁZQUEZ

Study Cohort



SECUKINUMAB
January 2017-February 2025


Materials and Methods



EFFECTIVENESS AT 24 WEEKS
Improvement in disease activity





PERSISTENCE
Kaplan-Meier survival curves




Distribution by line of treatment and initial dose.

EFFECTIVENESS RESULTS (24 WEEKS)



All treatment-naive patients achieved positive response, compared only to 3,3% inpatients treated in 4th line.

PERSISTENCE OF TREATMENT



No statistically significant differences in persistence were observed (p=0.44)

No statistically significant differences in persistence were observed (p=0.59)

Conclusion and relevance



BETTER RESPONSE IN TREATMENT-NAIVE PATIENTS.

Treatment-naïve patients had better outcomes, declining in later lines.



PERSISTENCE INDEPENDENT OF INITIAL DOSE AND TREATMENT LINE

No statistically significant differences in treatment persistence with the treatment line or initial dose.

